{"id":"placebo-janagliflozin","safety":{"commonSideEffects":[{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Polyuria"},{"rate":null,"effect":"Osmotic diuresis-related symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 (sodium-glucose cotransporter 2) inhibitors work by preventing the reabsorption of filtered glucose in the proximal tubule of the nephron. By blocking this transporter, the drug increases urinary glucose excretion (glycosuria), thereby reducing blood glucose independently of insulin secretion. This mechanism also provides cardiovascular and renal protective benefits beyond glucose lowering.","oneSentence":"Janagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:41.328Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03811548","phase":"PHASE3","title":"Janagliflozin Treat T2DM Monotherapy","status":"UNKNOWN","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","startDate":"2019-05-23","conditions":"Diabetes Type 2","enrollment":442},{"nctId":"NCT03851432","phase":"PHASE3","title":"Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin","status":"UNKNOWN","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","startDate":"2019-06-30","conditions":"Diabetes Mellitus, Type 2","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo/Janagliflozin","genericName":"Placebo/Janagliflozin","companyName":"Sihuan Pharmaceutical Holdings Group Ltd.","companyId":"sihuan-pharmaceutical-holdings-group-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Janagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}